Histology
Basal Cell Carcinoma
CI-CAN-00000479Explore in graph →
57 active trials4 approved drugs6 evidence items
Loading cancer entity…
Histology
CI-CAN-00000479Explore in graph →
Clinical trials
361 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (25)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00472459 | Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer | completed | Phase 3 | 82 | Galderma R&DINDUSTRY | 5 | Apr 18, 2025 | clinicaltrials |
| NCT00469417 | Metvix Photodynamic Therapy (PDT) Versus Cryotherapy in Participants With Primary Superficial Basal Cell Carcinoma | completed | Phase 3 | 120 | Galderma R&DINDUSTRY | 7 | Aug 19, 2024 | clinicaltrials |
| NCT00472043 | PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma | completed | Phase 3 | 66 | Galderma R&DINDUSTRY | 1 | Aug 6, 2024 | clinicaltrials |
| NCT00472108 | Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Cell Carcinoma | completed | Phase 3 | 65 | Galderma R&DINDUSTRY | 1 | Aug 5, 2024 | clinicaltrials |
| NCT00473343 | Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma | completed | Phase 3 | 102 | Galderma R&DINDUSTRY | 1 | Jan 5, 2023 | clinicaltrials |
| NCT02144077 | Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy | completed | Phase 3 | 281 | Biofrontera Bioscience GmbHINDUSTRY | 1 | Nov 3, 2022 | clinicaltrials |
| NCT00189280 | Aldara for the Treatment of Large and/or Multiple sBCC | completed | Phase 3 | 111 | MEDA Pharma GmbH & Co. KGINDUSTRY | 1 | Feb 22, 2022 | clinicaltrials |
| NCT00189241 | A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma | completed | Phase 3 | 160 | MEDA Pharma GmbH & Co. KGINDUSTRY | 1 | Feb 7, 2022 | clinicaltrials |
| NCT00005884 | Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer | completed | Phase 3 | — | University of Wisconsin, MadisonOTHER | 0 | Dec 13, 2019 | clinicaltrials |
| NCT02029352 | Topical Green Tea Ointment in Treatment of Superficial Skin Cancer | completed | Phase 2 / Phase 3 | 42 | Maastricht University Medical CenterOTHER | 1 | May 18, 2016 | clinicaltrials |
| NCT01260987 | Fractional CO2 Laser Assisted Photodynamic Therapy | completed | Phase 2 / Phase 3 | 47 | Bispebjerg HospitalOTHER | 1 | Jul 30, 2015 | clinicaltrials |
| NCT00066872 | Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer | completed | Phase 3 | 500 | Queen's Medical CenterOTHER | 1 | Sep 17, 2013 | clinicaltrials |
| NCT01212549 | Comparison of Two Schemes of Cryosurgery and Imiquimod Combination Treatment for Basal Cell Carcinoma(IMCXvsCIMT) | completed | Phase 3 | 14 | University of IoanninaOTHER | 1 | Sep 2, 2011 | clinicaltrials |
| NCT00189306 | Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream | completed | Phase 3 | 169 | Graceway Pharmaceuticals, LLCINDUSTRY | 2 | Aug 10, 2010 | clinicaltrials |
| NCT00129519 | A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence | completed | Phase 3 | 63 | Graceway Pharmaceuticals, LLCINDUSTRY | 1 | Jul 16, 2010 | clinicaltrials |
| NCT00007631 | Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer | completed | Phase 3 | 1,131 | US Department of Veterans AffairsFED | 1 | Jan 30, 2009 | clinicaltrials |
Data updated 22 days agoSource updated Apr 18, 2025source: clinicaltrials